Salesforce.com (CRM): Q1 EPS of $0.10 in-line. Revenue of $893M (+28% Y/Y) beats by $5.92M. Shares -4.2% AH. (PR) [View news story]
There is no path to GAAP (the real numbers) profitability for this company that I can see. IGNORE THE NON GAAP "ADJUSTED" EPS. If the company stops giving away company shares to employees or the stock starts going down, this business totally falls apart, IMHO.
Fundamentals For Salesforce.com Point To Higher Prices [View article]
"Oracle (ORCL) and SAP (SAP), both direct competitors, have market caps of over $90B and EBITDA values of $17.29B and $7.19B, respectively. CRM is small by comparison, with a market cap of about $24B and EBITDA of $84M. This data indicates room for growth and stock price increases as CRM figures more prominently with large-scale potential customers and clients."
On the contrary, the data indicates a hopelessly overvalued stock price with $30 or less written all over it.
It is not often that you find a biotech with so many possibilities for success at such a small market cap. The same can be said for Cytori Therapeutics, another favorite target of the shorts. That is what I like most about the risk/reward balance of the regressive medicine sector, ONE PLATFORM -----> MULTIPLE INDICATIONS. Good job, once again laying out the case for Athersys.
Trading Athersys: Risks And Rewards [View article]
As the initial blogger on Seeking Alpha to write-up anything on Athersys (http://seekingalpha.co...), I find the number of supporters responding here very encouraging. No one can KNOW for sure whether multi-stem for IBD progresses to the next level. I'm betting that it does. As others already mentioned, there is another substantive catalyst possible in the immediate future, the Allograft product with RTI Biologics where nilestone payments were pushed up at RTI's request in late 2012: http://bit.ly/13okJxP. We could see $30MM in milestone payments this year from this one product and licensing revenues soon after. Multi-Stem is a Multi-Indication therapy and Athersy does not need to hit on every therapy to be hugely successful. This stock has IRRATIONAL EXUBERANCE written all over it with just a couple of hits on its key catalysts, IMHO. Do your own DD.
Trading Athersys: Risks And Rewards [View article]
You seemed like you had a legitimate opinion on ATHX but it is pretty obvious you had a short term trade in mind. The enterprise value of ATHX is still less than $80 million, so it seems that your change in conviction, if you ever really had one, is nonsensical and/or dishonest. What exactly supports your analysis of a 5% success rate in IBD. Are you just grabbing that out of the air? Pfizer picked that indication as its best shot at success.
I might point out that, in the last year, insiders have only been buying, not one single sell: http://yhoo.it/ZxtOV0. There are no sure things but, in a situation where there is a binary event, insider buying and a lack of insider selling is as good an indication as any on success.
The RTI collaboration seems to be going very well. Note this excerpt from the 10-K were milestone payments were accelerated:
"We have also collaborated with RTI on the development of products for certain orthopedic applications using our stem cell technologies in the bone graft substitutes market. RTI’s product development activities are progressing, and we recently amended our agreement to accelerate $2.0 million of contingent milestone payments into 2012 in connection with technical support to assist RTI in its development efforts. We will also receive royalty revenue from product sales should they occur, as well as potential additional milestone payments."
Athersys (ATHX): Q4 EPS of -$0.07 beats by $0.03. Revenue of $2.3M beats by $0.6M. (PR) [View news story]
Earning beat or miss is meaningless at this point. However, after listening to the conference call, I can only reiterate my bullish assessment of this microcap called Athersys. Catalysts in the next 12 months are many and could be explosive. Partnership deal structured like the Pfizer transaction would double share price overnite, IMHO. But don't take my word for it, listen to the call and do your own DD.
Athersys: A Significantly Undervalued Stem Cell Company Approaching Key Catalysts [View article]
I have been following Athersys for a few years and have written a few articles on Seeking Alpha about the company (my last article was in August 2012: http://seekingalpha.co...). I must congratulate you on the high level of independent due diligence you performed to come to the same conclusion that I did. that ATHX is grossly undervalued. We could easily see a partnership for its Multi-Stem Cardiovascular Cell Therapy Program in 2013 as Atheresys was fortunate to regain complete control of this indication about a year ago from its former collaborator and partner, Angiotech Pharmaceuticals, Inc.: (http://seekingalpha.co...). As you point out, the management of this company is top notch and I appreciate the fact that they aren't overpaying themselves like some other competing stem cell companies. Congratulations once again on an excellent piece.
Having closed near its all-time high yesterday, Salesforce.com (CRM -2.6%) has spiked lower after filing a response to an SEC staff letter that was sent to CFO Graham Smith on Aug. 24. The letter asks for details about Salesforce's operating cash flow figures - in particular, the impact of working capital changes, the managing of accounts receivable, and factors that affect deferred revenue changes. It also asks Salesforce to break out U.S. sales, rather than just disclose Americas revenue. Some SA authors have taken aim at Salesforce's accounting in the past. [View news story]
How long will these Wall Street ANALysts give this company a free ride. NO EARNINGS --- $25,000,000,000 Market Cap. Since these bozos are ignoring earnings (i'm talking GAAP here) it will take a little hiccup in sales to sink this, IMHO.
Weak Trading In Athersys Following Share Dilution [View article]
Yes, the stock price has been dssapointing. However ther is much upside. My SA article from last August is worth a read for those who missed it: http://seekingalpha.co...
Salesforce.com (CRM): Q1 EPS of $0.10 in-line. Revenue of $893M (+28% Y/Y) beats by $5.92M. Shares -4.2% AH. (PR) [View news story]
Fundamentals For Salesforce.com Point To Higher Prices [View article]
On the contrary, the data indicates a hopelessly overvalued stock price with $30 or less written all over it.
Athersys, Inc: The Facts [View article]
Trading Athersys: Risks And Rewards [View article]
WST
Trading Athersys: Risks And Rewards [View article]
I might point out that, in the last year, insiders have only been buying, not one single sell: http://yhoo.it/ZxtOV0. There are no sure things but, in a situation where there is a binary event, insider buying and a lack of insider selling is as good an indication as any on success.
North Korean Threats And The Cytori - BARDA Stem Cell Collaboration [View article]
Athersys: Valuation [View article]
"We have also collaborated with RTI on the development of products for certain orthopedic applications using our stem cell technologies in the bone graft substitutes market. RTI’s product development activities are progressing, and we recently amended our agreement to accelerate $2.0 million of contingent milestone payments into 2012 in connection with technical support to assist RTI in its development efforts. We will also receive royalty revenue from product sales should they occur, as well as potential additional milestone payments."
Athersys (ATHX): Q4 EPS of -$0.07 beats by $0.03. Revenue of $2.3M beats by $0.6M. (PR) [View news story]
WST
Cytori's EU Approval For Intravase - Intentionally Downplayed? [View article]
WST
Athersys: The Coming Year Will Define MultiStem, Its Adult Stem Cell Product [View article]
WST
A Candid Conversation With Athersys CEO Gil Van Bokkelen [View article]
WST
Athersys: A Significantly Undervalued Stem Cell Company Approaching Key Catalysts [View article]
Having closed near its all-time high yesterday, Salesforce.com (CRM -2.6%) has spiked lower after filing a response to an SEC staff letter that was sent to CFO Graham Smith on Aug. 24. The letter asks for details about Salesforce's operating cash flow figures - in particular, the impact of working capital changes, the managing of accounts receivable, and factors that affect deferred revenue changes. It also asks Salesforce to break out U.S. sales, rather than just disclose Americas revenue. Some SA authors have taken aim at Salesforce's accounting in the past. [View news story]
Weak Trading In Athersys Following Share Dilution [View article]
Osiris Stem Cell Drug Approval Bodes Well For Athersys [View article]